2nd Quarter - Report

STANTON PARK GROUP for VERTEX PHARMACEUTICALS INCORPORATED

Firm
Client
Income
$50,000
Expenses
—

What was lobbied

One issue area, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

issues related to rare and orphan disease therapeutics; issues related to FDA regulatory pathways for pharmaceuticals; awareness of cystic fibrosis reauthorization of the Prescription Drug User Fee Amendments (PDUFA)

LobbyistCovered position, as disclosed
JAMES DERDERIAN —
SARAH HAMLETT New Legislative Director, Rep. Thelma Drake; Legislative Assistant, Rep. Schrock
VALERIE HENRY —
EMILY SHETTY —
ERIN STRAWN —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.